within Pharmacolibrary.Drugs.ATC.L;

model L03AB04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.28 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 36 / 1000000,
    adminCount     = 1,
    Vd             = 0.000223,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Interferon alfa-2a is a recombinant cytokine protein used as an immunomodulatory and antiviral agent. It is primarily used in the treatment of various cancers such as chronic myelogenous leukemia (CML), hairy cell leukemia, and malignant melanoma, as well as hepatitis B and C infections. It is approved for use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult healthy volunteers (both sexes) following subcutaneous administration.</p><h4>References</h4><ol><li><p>Costa, MB, et al., &amp; Saura, PL (2018). Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. <i>BMC pharmacology &amp; toxicology</i> 19(1) 1–None. DOI:<a href=&quot;https://doi.org/10.1186/s40360-017-0192-z&quot;>10.1186/s40360-017-0192-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29301580/&quot;>https://pubmed.ncbi.nlm.nih.gov/29301580</a></p></li><li><p>Miyachi, N, et al., &amp; Qin, A (2021). Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. <i>Clinical drug investigation</i> 41(4) 391–404. DOI:<a href=&quot;https://doi.org/10.1007/s40261-021-01026-5&quot;>10.1007/s40261-021-01026-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33725322/&quot;>https://pubmed.ncbi.nlm.nih.gov/33725322</a></p></li><li><p>Fülöp, B, et al., &amp; Berg, T (2015). Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. <i>Liver international : official journal of the International Association for the Study of the Liver</i> 35(10) 2275–2284. DOI:<a href=&quot;https://doi.org/10.1111/liv.12832&quot;>10.1111/liv.12832</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25801095/&quot;>https://pubmed.ncbi.nlm.nih.gov/25801095</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L03AB04;
